ClinicalTrials.Veeva

Menu
P

Peak Gastroenterology Associates | Peak Gastro Colorado Springs

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Etrasimod
Guselkumab
Relamorelin
Ontamalimab
Ozanimod
APT-1011
MK-7240
Etrolizumab
CC-93538
Elafibranor

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 57 total trials

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (E...

Active, not recruiting
Eosinophilic Esophagitis
Procedure: Esophagogastroduodenoscopy
Drug: Placebo oral tablet

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC).Participants will also have inadequate response or intolerance t...

Enrolling
Primary Biliary Cholangitis (PBC)
Drug: Elafibranor
Other: Matched 80 mg placebo

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Active, not recruiting
Crohn Disease
Other: Placebo
Drug: Ozanimod
Status recently updated

The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabol...

Enrolling
Active, not recruiting
Eosinophilic Esophagitis
Drug: Cendakimab
Drug: CYP substrates

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: Etrasimod
Status recently updated

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Enrolling
Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)

Enrolling
Coeliac Disease
Celiac Disease
Drug: KAN-101
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo
Locations recently updated

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo
Status recently updated

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Enrolling
Active, not recruiting
Colitis, Ulcerative
Drug: Placebo
Drug: JNJ-77242113
Locations recently updated

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Ustekinumab
Drug: Guselkumab Dose 3

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Enrolling
Primary Sclerosing Cholangitis
Drug: Placebo Matched to Elafibranor 80 mg
Drug: Placebo Matched to Elafibranor 120 mg

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: IV Placebo
Drug: SC Placebo

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evalu...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538
Other: Placebo

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's diseas...

Enrolling
Crohn's Disease
Other: SC Placebo
Drug: IV Tulisokibart

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod
Status recently updated

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

Enrolling
Active, not recruiting
Crohn Disease
Drug: Ozanimod

Trial sponsors

Celgene logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Shire logo
Allergan logo
E
Merck Sharp & Dohme (MSD) logo
A
A
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems